Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AHOD0431||COG||A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease||Pediatric CIRB||Completed|
|ADVL06B1||COG||A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer: A Group-Wide Non-Therapeutic Study||Pediatric CIRB||Completed|
|RTOG-P-0014||RTOG||A Phase III Randomized Study of Patients With High Risk; Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade with Delayed Chemotherapy" Study Closed and Terminated||Adult CIRB - Late Phase Emphasis||Completed|
|9653||ETCTN||Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder||Adult CIRB - Early Phase Emphasis||Completed|
|AAML05P1||COG||Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7; -5/5q-; High FLT3-ITD AR; or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study (A Groupwide Pilot Study)||Pediatric CIRB||Completed|
|GOG-0240||GOG||A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865; IND #113912) Versus the Non-Platinum Doublet; Topotecan Plus Paclitaxel; with and without NCI-Supplied Bevacizumab; in Stage IVB; Recurrent or Persistent Carcinoma of the Cervix||Adult CIRB - Late Phase Emphasis||Completed|
|EAQ161CD||ECOG-ACRIN||Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting||Cancer Prevention and Control CIRB||Completed|
|S0502||SWOG||A Phase III Randomized Study of Imatinib; with or without Bevacizumab (NSC-704865); in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors NCT #00324987||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-49907||CALGB||A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens; Cyclophosphamide; Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC); Versus Capecitabine in Women 65 Years and Older with Node Positive or Node Negative Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|9925||ETCTN||Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma||Adult CIRB - Early Phase Emphasis||Completed|